LeMaitre Vascular Inc
$ 85.70
0.92%
04 Dec - close price
- Market Cap 1,944,190,000 USD
- Current Price $ 85.70
- High / Low $ 86.79 / 83.16
- Stock P/E 36.94
- Book Value 16.71
- EPS 2.32
- Next Earning Report 2026-02-19
- Dividend Per Share $0.76
- Dividend Yield 0.89 %
- Next Dividend Date -
- ROA 0.08 %
- ROE 0.15 %
- 52 Week High 104.58
- 52 Week Low 70.94
About
LeMaitre Vascular, Inc. (LMAT) is a leading medical device company headquartered in Burlington, Massachusetts, specializing in innovative solutions for the treatment of peripheral vascular diseases. With a comprehensive portfolio that includes surgical tools and implants, LeMaitre Vascular is committed to enhancing the performance of vascular surgeons and improving patient outcomes. The company has solidified its reputation as a trusted partner in the vascular surgery market, highlighting its strategic focus on quality and innovation to meet the dynamic needs of healthcare providers globally. As the demand for advanced medical technologies continues to rise, LeMaitre Vascular is well-positioned to leverage its expertise and maintain growth in this critical sector.
Analyst Target Price
$104.33
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-07-30 | 2025-04-30 | 2025-02-25 | 2024-10-31 | 2024-08-01 | 2024-05-02 | 2024-02-27 | 2023-11-01 | 2023-08-01 | 2023-05-02 | 2023-02-23 |
| Reported EPS | 0.62 | 0.6 | 0.48 | 0.49 | 0.49 | 0.52 | 0.44 | 0.38 | 0.33 | 0.36 | 0.27 | 0.25 |
| Estimated EPS | 0.57 | 0.5667 | 0.4978 | 0.49 | 0.44 | 0.47 | 0.39 | 0.36 | 0.3 | 0.32 | 0.25 | 0.26 |
| Surprise | 0.05 | 0.0333 | -0.0178 | 0 | 0.05 | 0.05 | 0.05 | 0.02 | 0.03 | 0.04 | 0.02 | -0.01 |
| Surprise Percentage | 8.7719% | 5.8761% | -3.5757% | 0% | 11.3636% | 10.6383% | 12.8205% | 5.5556% | 10% | 12.5% | 8% | -3.8462% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-19 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.6625 |
| Currency | USD |
Previous Dividend Records
| Dec 2025 | Sep 2025 | May 2025 | Jan 1970 | Mar 2025 | Dec 2024 | Aug 2024 | May 2024 | Mar 2024 | Nov 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2025-12-04 | 2025-09-04 | 2025-05-29 | None | 2025-03-27 | 2024-12-05 | 2024-08-29 | 2024-05-30 | 2024-03-28 | 2023-11-30 |
| Amount | $0.2 | $0.2 | $0.2 | $0.2 | $0.2 | $0.16 | $0.16 | $0.16 | $0.16 | $0.14 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LMAT
2025-10-19 09:14:02
This article analyzes Lemaitre Vascular Inc. (LMAT) using AI models, indicating a neutral sentiment across all time horizons and suggesting a wait-and-see approach. It details three distinct trading strategies (Position Trading, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels. The analysis highlights an exceptional 40.1:1 risk-reward setup targeting an 11.4% gain versus a 0.3% risk.
2025-10-15 13:08:45
Barrington Research maintained its "Outperform" rating and $95.00 price target for LeMaitre Vascular (LMAT) following an analyst update on October 15, 2025. This decision mirrors prior ratings and reflects sustained analyst confidence in the medical device company. Wall Street analysts forecast an average price target of $104.63 for LMAT, suggesting a 19.74% upside from its current price, and a consensus "Outperform" recommendation.
2025-10-10 00:53:00
LeMaitre Vascular, Inc. announced that it will release its third quarter 2025 financial results on Thursday, November 6, 2025, after market close. The company will also hold a conference call the same day at 5:00 PM EST to discuss the results, business highlights, and company outlook. Investors can register online to access the live call, or access the audio webcast and replay at ir.lemaitre.com.
2025-08-05 16:05:00
LeMaitre Vascular, Inc. reported strong Q2 2025 financial results, with sales of $64.2 million, up 15%, and diluted EPS of $0.60, also up 16%. The company increased its full-year 2025 guidance for both sales and profit, citing strong performance in catheters and grafts and the OUS launch of Artegraft. LeMaitre also announced a quarterly dividend of $0.20 per share and discussed its share repurchase program.
2025-06-18 00:00:00
LeMaitre Vascular's high P/E ratio of 40.5x, significantly above the U.S. market average, is questioned despite its recent strong earnings growth of 32% over the last year and 59% over three years. Although analysts forecast future annual earnings growth of 10%, matching the broader market, the article suggests that the high P/E might not be justified and could pose a risk to the share price. Investors may be overly bullish compared to analyst expectations, leading to a potentially unsustainable valuation.
2020-06-23 22:46:04
LeMaitre Vascular announced the acquisition of Artegraft for $90 million, consisting of $72.5 million in cash at closing and an additional $17.5 million in potential earnout payments. This acquisition aims to augment LeMaitre's product offering, making Artegraft's biologic vascular grafts a cornerstone for vascular surgeons and patients with end-stage renal disease, particularly in the U.S. Artegraft will continue its North Brunswick, N.J., manufacturing for at least 3.5 years, retaining most of its employees.
